Denali Therapeutics Inc (OQ:DNLI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 161 Oyster Point Blvd
Tel: N/A
IR: See website
Key People
Vicki L. Sato
Independent Chairman of the Board
Ryan J. Watts
President, Chief Executive Officer, Co-Founder, Director
Alexander O. Schuth
Co-Founder, Chief Operating Officer, Secretary
Steve E. Krognes
Chief Financial Officer, Treasurer
Carole Ho
Chief Medical Officer, Head of Development
Business Overview
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company's development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
Financial Overview
For the three months ended 31 March 2020, Denali Therapeutics Inc revenues decreased 14% to $3.6M. Net loss increased 46% to $56.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research & Development Expense - Balanci increase of 35% to $45M (expense), Stock-based Compensation in R&D increase of 52% to $6.1M (expense).
Employees: 268 as of Mar 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $2,352M as of Mar 31, 2020
Annual revenue (TTM): $26.08M as of Mar 31, 2020
EBITDA (TTM): -$222.95M as of Mar 31, 2020
Net annual income (TTM): -$215.39M as of Mar 31, 2020
Free cash flow (TTM): -$192.52M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 105,628,182 as of Apr 29, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization